EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer

Yuexiao Song iD, Changchun Shao iD, Yiruo Zhang iD, Min Yang iD, Yaqian Liu iD, Sheng Chen, Jia Gao iD, Zihuan Li, Bin Li, Xuebiao Yao iD, Xing Liu iD, Ke Ruan iD und 1 weitere

Protein & Cell · 01.11.2026 · 17 (11) · 1021-1034

DOI: 10.1093/procel/pwag043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein & Cell, online erschienen am 26.06.2026. Verfasst von Yuexiao Song und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Lung Neoplasms, Protein Kinase Inhibitors, Sequestosome-1 Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, National Natural Science Foundation Youth Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer remains a pressing clinical challenge. Liquid-liquid phase separation has emerged as a new mechanism of drug resistance, yet its role in EGFR-TKI resistance in lung cancer is largely unexplored. Herein, we prioritized Sequestosome 1 (SQSTM1/p62) as a key condensate by integrating proteomics data from EGFR-TKI resistance cell lines and clinical biopsy specimens, in which the cytoplasmic p62 condensate formation positively correlated with EGFR-TKI resistance. Domain mapping demonstrated that the PB1 and UBA domains of p62 were critical for promoting phase separation and reducing sensitivity to EGFR-TKI treatment, whereas S403 phosphorylation promoted p62 condensation and EGFR-TKI resistance. Further xenograft studies validated that reduction of p62 condensation restores EGFR-TKI sensitivity. Kinase enrichment and interaction assays identified TBK1 as an upstream regulator of p62 S403 phosphorylation to promote p62 condensation after pharmacological inhibition of EGFR. Notably, among the five compounds identified from a drug library screen that both disrupted p62 condensate formation and inhibited the viability of resistant cells, the highly selective TBK1 inhibitor GSK8612 stood out. GSK8612 inhibited p62 S403 phosphorylation and consequently, at subcytotoxic doses, synergized with EGFR-TKIs to suppress the viability of resistant cells and tumor growth in the xenograft mouse model. These findings propose TBK1-p62 axis links p62 condensate homeostasis to EGFR-TKI resistance as an underlying mechanism of action and an emerging strategy to resensitize EGFR-TKI treatment in resistant lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmLung NeoplasmsProtein Kinase InhibitorsSequestosome-1 ProteinProtein Serine-Threonine KinasesCarcinoma, Non-Small-Cell LungHumansAnimalsErbB ReceptorsCell Line, TumorMicePhosphorylation

Stichwörter der Autor:innen

EGFR-TKI resistanceSQSTM1/p62TBK1biomolecular condensatesliquid-liquid phase separation (LLPS)lung cancer

Substanzen

Protein Kinase InhibitorsSequestosome-1 ProteinErbB ReceptorsProtein Serine-Threonine KinasesSQSTM1 protein, humanTBK1 protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
  • The First Clinical Medical College, Anhui University of Chinese Medicine, Hefei 230022, China.
  • Foresight Therapeutics (Hefei), Co., Ltd, Hefei 230022, China.
  • Department of Oncology, The First Affiliated Hospital & School of Life Sciences, Ministry of Education Key Laboratory for Membrane-less Organelles & Cellular Dynamics, Hefei National Research Center for Interdisciplinar…
  • Department of Oncology, The Fifth Affiliated Hospital of Anhui Medical University, Fuyang 236000, China.

ORCID-Profile: Yuexiao Song, Changchun Shao, Yiruo Zhang, Min Yang, Yaqian Liu, Jia Gao, Xuebiao Yao, Xing Liu, Ke Ruan, Yingying Du

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • National Natural Science Foundation Youth Program
  • Research Funds of Center for Advanced Interdisciplinary Science and Biomedicine of IHM
  • USTC Research Funds of the Double First-Class Initiative
  • Natural Science Research Project of Anhui Educational Committee
  • Chinese Thoracic Oncology Group
  • Inflammation and Immune Mediated Diseases Laboratory of Anhui Province

Zitieren

APA

Song, Y., Shao, C., Zhang, Y., Yang, M., Liu, Y., Chen, S., Gao, J., Li, Z., Li, B., Yao, X., Liu, X., Ruan, K., & Du, Y. (2026). Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer. Protein & Cell, 17(11), 1021-1034. https://doi.org/10.1093/procel/pwag043

Vancouver

Song Y, Shao C, Zhang Y, Yang M, Liu Y, Chen S, et al. Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer. Protein & Cell. 2026;17(11):1021-1034. doi:10.1093/procel/pwag043

BibTeX
@article{Song2026,
  author = {Song, Yuexiao and Shao, Changchun and Zhang, Yiruo and Yang, Min and Liu, Yaqian and Chen, Sheng and Gao, Jia and Li, Zihuan and Li, Bin and Yao, Xuebiao and Liu, Xing and Ruan, Ke and Du, Yingying},
  title = {Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer},
  journal = {Protein & Cell},
  year = {2026},
  volume = {17},
  number = {11},
  pages = {1021--1034},
  doi = {10.1093/procel/pwag043}
}
Kostenlos starten →